A Study on Pharmaceutical Drug Recall

Bansi l. Bhalodiya, Amit Kumar J. Vyas, Ajay I. Patel, Ashvin V. Dudhrejiya, Ashok B. Patel
{"title":"A Study on Pharmaceutical Drug Recall","authors":"Bansi l. Bhalodiya, Amit Kumar J. Vyas, Ajay I. Patel, Ashvin V. Dudhrejiya, Ashok B. Patel","doi":"10.52711/2231-5691.2023.00020","DOIUrl":null,"url":null,"abstract":"The present study describes the pharmaceutical drug recall in different five countries to evaluate the drug recall that occurred in the last three successive years. The different countries have different regulations for drug recall. Drug product recall is an action taken to withdraw or remove a batch or an entire production run of drug product from distribution or use to return them to manufacturer.it is usually done due to deficiency in quality, safety and efficacy. In the USA, guidelines for drugs product recall are described under 21 CFR Parts 7, 107 and 1270. In Australia, guidelines for drugs product recall are described under section 65F of trade practices act 1974. In Canada, it includes under section 25 of Natural Health Products Regulations (NHPR). In India it includes under para 27 and 28 of schedule M. In South Africa SAHPRA (South African Health Products Regulatory Authority) guidelines are responsible for regulations of drug product recall. Majority of drug recalls occur in the United states due to various reasons. In 2020-2022 total 257 drugs were recalled in Last three years. In Canada and Australia 220 and 25 drugs are recalled respectively. India and South Africa have recalled 2 and 21 drugs respectively. By the observation we can conclude that India and South Africa have a smaller number of recalls. In the USFDA number of drug recalls are decreasing due to following up the laws and regulatory.","PeriodicalId":8537,"journal":{"name":"Asian Journal of Pharmaceutical Research","volume":"9 3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52711/2231-5691.2023.00020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The present study describes the pharmaceutical drug recall in different five countries to evaluate the drug recall that occurred in the last three successive years. The different countries have different regulations for drug recall. Drug product recall is an action taken to withdraw or remove a batch or an entire production run of drug product from distribution or use to return them to manufacturer.it is usually done due to deficiency in quality, safety and efficacy. In the USA, guidelines for drugs product recall are described under 21 CFR Parts 7, 107 and 1270. In Australia, guidelines for drugs product recall are described under section 65F of trade practices act 1974. In Canada, it includes under section 25 of Natural Health Products Regulations (NHPR). In India it includes under para 27 and 28 of schedule M. In South Africa SAHPRA (South African Health Products Regulatory Authority) guidelines are responsible for regulations of drug product recall. Majority of drug recalls occur in the United states due to various reasons. In 2020-2022 total 257 drugs were recalled in Last three years. In Canada and Australia 220 and 25 drugs are recalled respectively. India and South Africa have recalled 2 and 21 drugs respectively. By the observation we can conclude that India and South Africa have a smaller number of recalls. In the USFDA number of drug recalls are decreasing due to following up the laws and regulatory.
药品召回研究
本研究描述了五个国家的药品召回情况,以评估最近连续三年发生的药品召回情况。各国对药品召回有不同的规定。药品召回是指从销售或使用中撤回或移除一批或整个生产批次的药品,并将其退还给制造商的行动。通常是由于质量、安全性和有效性方面的不足而进行的。在美国,药品召回指南在21 CFR第7、107和1270部分中有描述。在澳大利亚,1974年《贸易惯例法》第65F节描述了药品召回的指导方针。在加拿大,根据《天然保健产品条例》(NHPR)第25条,它包括在内。在印度,它包括附表m第27和28段。在南非,南非保健产品管理局(SAHPRA)的准则负责药品召回的规定。由于各种原因,大多数药品召回发生在美国。2020-2022年,近三年共召回257种药品。加拿大和澳大利亚分别召回220种和25种药物。印度和南非分别召回了2种和21种药物。通过观察,我们可以得出结论,印度和南非的召回数量较少。在美国食品药品监督管理局,由于法律法规的跟进,药品召回的数量正在减少。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信